The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Phase III VERONA study of venetoclax with azacitidine in treatment-naïve higher-risk MDS
Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the randomized, double-blind Phase III VERONA study (NCT04401748), a trial-in-progress evaluating venetoclax with azacitidine to assess the change in complate remission and overall survival in treatment-naive higher risk myelodsyplastic syndromes (MDS). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
